This study focuses on people with episodic migraine or chronic migraine, which are conditions causing severe headaches. The research evaluates a new medication called IPN10200, which contains Clostridium botulinum neurotoxin, administered as an intramuscular injection. Some participants will receive the study medication while others will receive a placebo. The purpose is to determine if IPN10200 is effective in preventing migraines and to assess its safety.
The study medication or placebo will be given as a single treatment cycle. Throughout the study, participants will need to track their headaches and migraine days using an electronic diary. The study will monitor various aspects of participants’ health, including any changes in their condition and how their body responds to the treatment. The total duration of participation for each person will be 36 weeks.
During the study, researchers will evaluate how the treatment affects the number of days participants experience migraines each month. They will also monitor the use of other migraine medications and assess whether the study medication helps reduce both the frequency and severity of headaches. Regular health checks will be performed to ensure participant safety throughout the study period.
Czechia 
France 
Germany 
Poland 
Spain 
